Pfizer Inc. $PFE Shares Sold by Trust Co. of Vermont

Trust Co. of Vermont reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 14.8% in the 4th quarter, HoldingsChannel reports. The firm owned 184,643 shares of the biopharmaceutical company’s stock after selling 32,076 shares during the period. Trust Co. of Vermont’s holdings in Pfizer were worth $4,598,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in PFE. Penn Davis Mcfarland Inc. increased its position in Pfizer by 50.9% during the 4th quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock worth $4,266,000 after purchasing an additional 57,777 shares during the period. Kwmg LLC lifted its holdings in Pfizer by 5.8% in the fourth quarter. Kwmg LLC now owns 224,603 shares of the biopharmaceutical company’s stock valued at $5,593,000 after acquiring an additional 12,295 shares during the period. Compagnie Lombard Odier SCmA boosted its holdings in Pfizer by 1.7% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 386,225 shares of the biopharmaceutical company’s stock worth $9,617,000 after buying an additional 6,532 shares in the last quarter. Capital Advisors Inc. OK boosted its stake in shares of Pfizer by 6.9% during the 4th quarter. Capital Advisors Inc. OK now owns 1,640,726 shares of the biopharmaceutical company’s stock worth $40,854,000 after acquiring an additional 105,365 shares in the last quarter. Finally, Victory Financial Group LLC boosted its position in Pfizer by 27.9% during the fourth quarter. Victory Financial Group LLC now owns 14,124 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 3,084 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Belgian court ordered Poland and Romania to accept €1.9B (~$2.2B) of Pfizer COVID-19 vaccines, effectively locking in substantial near-term revenue and reducing delivery/collection uncertainty. Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines
• Positive Sentiment: Analyst/market write-ups highlight PFE’s recent outperformance and upward technical momentum (trading above its 50- and 200-day SMAs, and positive earnings beats), which supports demand for the stock. Why Pfizer (PFE) Outpaced the Stock Market Today
• Positive Sentiment: Fresh real‑world data from a Swedish study on Ibrance (palbociclib) offers an incremental clinical signal for Pfizer’s oncology franchise, supporting pipeline upside expectations. Pfizer’s Swedish Ibrance Study: Fresh Real‑World Data Signal for PFE Investors
• Neutral Sentiment: Pfizer finalized reshaping of ViiV Healthcare ownership (GSK/Shionogi deal) as it exits the joint HIV venture — a strategic reallocation that may free capital but reduces direct exposure to that HIV business. GSK and Shionogi Reshape ViiV Healthcare Ownership as Pfizer Exits HIV Venture
• Neutral Sentiment: Background and business-model pieces continue to circulate (how Pfizer makes money, sector commentary), useful for context but not immediate catalysts. How Pfizer Makes Money
• Negative Sentiment: Pfizer and BioNTech paused U.S. recruitment for a large updated COVID vaccine trial (adults 50–64) due to low enrollment — a setback for collecting pivotal U.S. data and could delay future vaccine updates or label expansion. Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles
• Negative Sentiment: Critical pieces argue Pfizer’s large dividend may mask underlying growth challenges, keeping longer-term valuation concerns on investors’ radar. Bearish on Pfizer (PFE) as Big Dividend Fails to Mask the Growth Problem
• Negative Sentiment: Reports that Pfizer will close its South San Francisco research site may signal internal cost-cutting or pipeline reprioritization; this can be seen as short-term disruption to R&D capacity. Pfizer is said to close South San Francisco research site

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday, February 4th. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a report on Monday, March 2nd. HSBC increased their price target on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. BMO Capital Markets reissued an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a research note on Monday, March 9th. Finally, Guggenheim upped their target price on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.19.

Pfizer Price Performance

PFE opened at $28.56 on Thursday. The company’s 50 day simple moving average is $26.99 and its 200 day simple moving average is $25.77. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $28.64. The stock has a market capitalization of $162.41 billion, a PE ratio of 21.00 and a beta of 0.43.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same quarter in the prior year, the business posted $0.63 earnings per share. Pfizer’s revenue for the quarter was down 1.2% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.